Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors Reply

Pan Kathy; Bosserman Linda; Chlebowski Rowan T.

首页> 外文期刊>Journal of Clinical Oncology >Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors Reply

【24h】

Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors Reply

机译：Exemestane Plus卵巢功能抑制是患有内分泌响应乳腺癌的最佳辅助治疗较高的复发风险和Her2阴性肿瘤的答复

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Clinical Oncology》 |2019年第21期|共3页
作者
Pan Kathy; Bosserman Linda; Chlebowski Rowan T.;
展开▼
作者单位

Harbor UCLA Med Ctr Los Angeles Biomed Res Inst Torrance CA 90509 USA;

City Hope Natl Med Ctr 1500 E Duarte Rd Duarte CA 91010 USA;

Harbor UCLA Med Ctr Los Angeles Biomed Res Inst Torrance CA 90509 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors Reply [J] . Pan Kathy, Bosserman Linda, Chlebowski Rowan T. Journal of Clinical Oncology . 2019,第21期

机译：Exemestane Plus卵巢功能抑制是患有内分泌响应乳腺癌的最佳辅助治疗较高的复发风险和Her2阴性肿瘤的答复
2. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy [J] . Bellet Meritxell, Gray Kathryn P., Francis Prudence A., Journal of Clinical Oncology . 2016,第14期

机译：激素受体阳性乳腺癌的绝经前妇女在抑制卵巢功能试验中接受曲普瑞林加依西美坦或他莫昔芬辅助治疗的十二个月雌激素水平（SOFT）：SOFT-EST子研究
3. Continued use of goserelin to achieve ovarian function suppression in combination with a further aromatase inhibitor (exemestane) following prior treatment with anastrozole and/or tamoxifen in premenopausal women with oestrogen receptor positive advanced breast cancer [J] . A.Agrawal, Robertson, L.Winterbottom, European Journal of Cancer Supplements . 2006,第2期

机译：事先使用阿那曲唑和/或他莫昔芬治疗患有雌激素受体阳性的绝经前妇女后，继续与其他芳香化酶抑制剂（依西美坦）合用戈舍瑞林以抑制卵巢功能
4. Association of bone mineral density and mammographic breast density in premenopausal and postmenopausal Malaysian women: Study on women with and without breast cancer [C] . Norhayati Mohd Zain, Vengkatha Priya Seriramulu, Kanaga Kumari Chelliah, International Conference on Bio-engineering for Smart Technologies . 2016

机译：绝经前和绝经后马来西亚女性的骨矿物质密度与乳房X线照片乳房密度的关系：有无乳腺癌的女性研究
5. An Increased BMI Associated with an Increased Risk of Developing ER Negative Breast Cancer among Premenopausal African American Women [D] . Megreisi, Sara 2018

机译：绝经前非洲裔美国妇女中的BMI升高与发生ER阴性乳腺癌的风险增加相关
6. Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors [O] . Fabio Conforti, Laura Pala -1

机译：Exemestane加卵巢功能抑制是绝经前妇女的最佳辅助治疗该绝经前妇女患有内分泌反应性乳腺癌且复发风险较高且HER2阴性肿瘤。
7. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy [O] . Bellet, Meritxell, Gray, Kathryn, Gonzales-Martin, Antonio, 2016

机译：接受曲普瑞林联合依西美坦或他莫昔芬治疗卵巢功能抑制试验的绝经前妇女激素受体阳性乳腺癌的十二个月雌激素水平：SOFT-EST子研究

Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors Reply

著录项

相似文献

相关主题

期刊订阅